Remove Contract Manufacturing Remove Hormones Remove Trials
article thumbnail

(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Genital Warts (Condylomata Acuminata): Likelihood of Approval

Pharmaceutical Technology

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The company also offers contract manufacturing and laboratory services.

article thumbnail

(Lopinavir + ritonavir) by Douglas Pharmaceuticals for Cervical Intraepithelial Neoplasia (CIN): Likelihood of Approval

Pharmaceutical Technology

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The company also offers contract manufacturing and laboratory services.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Lumos Pharma’s Patient-Centric Strategy for Rare Disease Drug Development

XTalks

Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. This rare endocrine disorder, characterized by inadequate secretion of growth hormone from the pituitary gland, has profound impacts on physical and sometimes cognitive development.

article thumbnail

Enzalutamide by Pfizer for Relapsed Multiple Myeloma: Likelihood of Approval

Pharmaceutical Technology

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. Enzalutamide overview Enzalutamide (Xtandi) is a phenylimidazolidine derivative, acts as anti neoplastic agent.

Hormones 113
article thumbnail

Enzalutamide by Pfizer for Myelofibrosis: Likelihood of Approval

Pharmaceutical Technology

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. Enzalutamide overview Enzalutamide (Xtandi) is a phenylimidazolidine derivative, acts as anti neoplastic agent.

Hormones 100
article thumbnail

Enzalutamide by Pfizer for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Pharmaceutical Technology

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. Enzalutamide overview Enzalutamide (Xtandi) is a phenylimidazolidine derivative, acts as anti neoplastic agent.

Hormones 100
article thumbnail

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

The Pharma Data

billion, primarily driven by Pfizer CentreOne, Pfizer’s contract manufacturing operation, reflecting sales of legacy Upjohn products to Viatris (4) and remdesivir to Gilead Sciences Inc., Vaccine effectiveness in the study will be inferred through immunobridging to the 16 to 25 year-old population in the pivotal Phase 3 trial.